Table 1.
Cytogenetic, molecular, and GD biomarkers evolution
| Follow‐up | Cytogenetic/molecular response | CML therapy | GD biomarkers CHT (nmol/mL/h)/CCL18 (ng/mL) |
|---|---|---|---|
| CML Dx | 95% Ph+ | 1692/722 | |
| 1 month | CHR | Ima 400 mg/day | |
| 3 months | 12%, PCyR; 19% | Ima 200 mg/day, restarted 400 mg/day | |
| 6 months | CCyR; 0.3%, MR2 | Ima 400 mg/day | 361/492 |
| 9 months | CCyR; 0.18%, MR2 | Ima 400 mg/day | |
| 12 months | CCyR; 0.15%, MR2 | Ima 400 mg/day | 400/478 |
| 18 months | Mutation: p.Tyr342His (Y342H). | Dasatinib 100 mg/day | 668/256 |
| 24 months | CCyR; 0.09% MR3 | Dasatinib 100 mg/day | 412/200 |
| 30 months | CCyR; 0.05% MR3 | Dasatinib 100 mg/day | 563/209 |
Dx, diagnosis; CML, chronic myeloid leukemia; CHT, chitotriosidase; PCyR, partial cytogenetic response, CCyR, complete CyR; MR2, ‐2 log reduction on BCR‐ABL/ABL transcript level.